Atsena Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
32
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$150M
- Investors
-
13
Atsena Therapeutics General Information
Description
Developer of ocular gene therapies designed to reverse or prevent blindness. The company's programs include treatments for leading forms of Leber congenital amaurosis and Usher syndrome and have a pipeline powered by associated virus technology, enabling healthcare professionals to reverse or prevent blindness and overcome the hurdles presented by inherited retinal disease.
Contact Information
Website
www.atsenatx.comCorporate Office
- 8 Davis Drive
- Suite 300
- Durham, NC 27709
- United States
Corporate Office
- 8 Davis Drive
- Suite 300
- Durham, NC 27709
- United States
Atsena Therapeutics Timeline
Atsena Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 02-Apr-2025 | $150M | Completed | Clinical Trials - Phase 2 | ||
| 3. Early Stage VC (Series B) | 02-Oct-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 16-Dec-2020 | $55M | $63.1M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series 1) | 01-Apr-2020 | $8.15M | $8.15M | Completed | Clinical Trials - Phase 1 |
Atsena Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-3 | ||||||||
| Series C-2 | ||||||||
| Series C-1 | ||||||||
| Series B | ||||||||
| Series A | 13,986,921 | $0.000100 | 7% | $3.81 | $3.81 | 1x | $3.81 | 17% |
| Series 1 | 4,201,020 | $0.000100 | 7% | $1.94 | $1.94 | 1x | $1.94 | 5.11% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Atsena Therapeutics Comparisons
Industry
Financing
Details
Atsena Therapeutics Competitors (1)
One of Atsena Therapeutics’s competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Atsena Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Atsena Therapeutics Patents
Atsena Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026085386-A1 | Methods for treating xlrs | Pending | 18-Oct-2024 | ||
| AU-2024265002-A1 | Dual aav vectors for treating stargardt disease | Pending | 01-May-2023 | ||
| EP-4704917-A1 | Dual aav vectors for treating stargardt disease | Pending | 01-May-2023 | ||
| JP-2026516065-A | Dual aav vectors for treating stargardt disease | Pending | 01-May-2023 | ||
| US-20260295092-A1 | Dual aav vectors for treating stargardt disease | Pending | 01-May-2023 | A61K48/0058 |
Atsena Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Atsena Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bain Capital | PE/Buyout | Minority | ||
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| Wellington Management | Asset Manager | Minority | ||
| Abingworth | Venture Capital | Minority | ||
| Lightstone Ventures | Venture Capital | Minority |
Atsena Therapeutics Investments (1)
Atsena Therapeutics’s most recent deal was a Corporate Asset Purchase with Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights). The deal was made on 29-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Atsena Therapeutics (Gene Therapy GUCY2D exclusive rights) | 29-Jul-2020 | Corporate Asset Purchase | Buildings and Property |
Atsena Therapeutics FAQs
-
When was Atsena Therapeutics founded?
Atsena Therapeutics was founded in 2019.
-
Where is Atsena Therapeutics headquartered?
Atsena Therapeutics is headquartered in Durham, NC.
-
What is the size of Atsena Therapeutics?
Atsena Therapeutics has 32 total employees.
-
What industry is Atsena Therapeutics in?
Atsena Therapeutics’s primary industry is Drug Discovery.
-
Is Atsena Therapeutics a private or public company?
Atsena Therapeutics is a Private company.
-
What is the current valuation of Atsena Therapeutics?
The current valuation of Atsena Therapeutics is .
-
What is Atsena Therapeutics’s current revenue?
The current revenue for Atsena Therapeutics is .
-
How much funding has Atsena Therapeutics raised over time?
Atsena Therapeutics has raised $238M.
-
Who are Atsena Therapeutics’s investors?
Bain Capital, Bain Capital Life Sciences, Wellington Management, Abingworth, and Lightstone Ventures are 5 of 13 investors who have invested in Atsena Therapeutics.
-
Who are Atsena Therapeutics’s competitors?
Alnylam Pharmaceuticals is a competitor of Atsena Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
